In a study conducted on 40 patients with a melanoma diagnosis, Khattack et al. found that the number of PD-L1+ CTCs was higher in patients responding to Pembrolizumab compared to non-responders at the baseline [179]. The gene discussed is CD274; the disease is melanoma.